You are here
News Release
Wednesday, March 21, 2012
Study provides clues for designing new anti-addiction medications
NIH-funded research shows 3D model of activity on key receptor.
Scientists are now one step closer to developing anti-addiction medications, thanks to new research that provides a better understanding of the properties of the only member of the opioid receptor family whose activation counteracts the rewarding effects of addictive drugs. The study was supported by the National Institute on Drug Abuse (NIDA), the National Institute of General Medical Sciences and the National Institute of Mental Health, all components of the National Institutes of Health.
“Drug abuse and addiction remain devastating public health challenges in the United States,” said NIDA Director Dr. Nora D. Volkow. “This research could aid in the development of effective medications for the treatment of drug addiction, particularly to stimulants like cocaine, for which there are no medications currently available. It may also be valuable for the development of safer pain medications.”
Unlike the other opioid receptor subtypes, the kappa opioid receptor (KOR) is not associated with the development of physical dependence or the abuse potential of opiate drugs (e.g., heroin, morphine). Therefore, medications that act at the KOR could have broad therapeutic potential for addressing addiction, pain, as well as other mental disorders. The leading compound in this context is JDTic because its specific binding to the KOR has been shown to reduce relapse to cocaine seeking in animal models. JDTic is currently in clinical trials to assess its safety and tolerability in humans.
In this new study, scientists produced a high resolution three-dimensional image of JDTic bound to the human KOR. By mapping all the points of contact between JDTic and the human KOR, researchers were able to see how the two fit together. The emerging picture reveals critical new information that helps explain why JDTic binds so tightly and specifically to this particular opioid receptor. This advance opens the door to the development of compounds targeting the KOR with improved therapeutic profiles, including that of non-addictive pain medications.
The study by Wu et al., can be found at: www.nature.com. For information on prescription drug abuse, go to: www.drugabuse.gov/drugs-abuse/prescription-medications.
The National Institute on Drug Abuse is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug abuse and addiction. The Institute carries out a large variety of programs to inform policy and improve practice. Fact sheets on the health effects of drugs of abuse and information on NIDA research and other activities can be found on the NIDA home page at www.drugabuse.gov, which is now compatible with your smartphone, iPad or tablet. To order publications in English or Spanish, call NIDA’s DrugPubs research dissemination center at 1-877-NIDA-NIH or 240-645-0228 (TDD) or fax or email requests to 240-645-0227 or drugpubs@nida.nih.gov. Online ordering is available at http://drugpubs.drugabuse.gov. NIDA’s media guide can be found at http://drugabuse.gov/mediaguide/, and its new easy-to-read website can be found at www.easyread.drugabuse.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health®